Targeting an MMP-9-activated Prodrug to Multiple Myeloma-Diseased Bone Marrow: A Proof of Principle in the 5T33MM Mouse Model

Leukemia - United Kingdom
doi 10.1038/sj.leu.2403866
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Bone Marrow Angiogenesis in Multiple Myeloma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Different Presentation of Multiple Myeloma in Bone Marrow Aspiration

Journal of Cancer Science and Clinical Therapeutics
2018English

Sorafenib Has Potent Antitumor Activity Against Multiple Myeloma in Vitro, Ex Vivo, and in Vivo in the 5T33MM Mouse Model

Cancer Research
Cancer ResearchOncology
2012English

Ficolled Bone Marrow Is Superior to Bone Marrow Buffy Coat for Detection of Minimal Residual Disease in Multiple Myeloma

Hematology
Hematology
2019English

Effect of Thalidomide Therapy on Bone Marrow Angiogenesis in Multiple Myeloma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2004English

Bone Marrow IRF4 Level in Multiple Myeloma: An Indicator of Peripheral Blood Th17 and Disease

Oncotarget
Oncology
2017English

Identification of Malignant Plasma Cell Precursors in the Bone Marrow of Multiple Myeloma.

Journal of Clinical Investigation
Medicine
1985English

The Histopathology of Myeloma in the Bone Marrow

Journal of clinical and experimental hematopathology : JCEH
Medicine
2018English

Extracellular Vesicle Cross-Talk in the Bone Marrow Microenvironment: Implications in Multiple Myeloma

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy